Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Yu, Di ^a   Jin, Chuan ^a   Ramachandran, Mohanraj ^a   Xu, Jing ^a   Nilsson, Berith ^a   Korsgren, Olle ^a   Le Blanc, Katarina ^b   Uhrbom, Lene ^a   Forsberg Nilsson, Karin ^a   Westermark, Bengt ^a   Adamson, Rachel ^c   Maitland, Norman ^c   Fan, Xiaolong ^d,e   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF YORK   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e BEIJING NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; TRANSACTIVATOR PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; EXOCRINE CELL; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MACROPHAGE; MESENCHYMAL STEM CELL; MONOCYTE; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PLASMID; PRIMARY CELL CULTURE; PROTEIN MODIFICATION; SURFACE PROPERTY; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; CELL LINE; GENE ORDER; GENETIC VECTORS; HUMANS; MICE; PRIMARY CELL CULTURE; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; COXSACKIEVIRUS; MUS; REPLICATION COMPETENT VIRUSES;

EID: 84872866042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054952     Document Type: Article

References (49)

1. Magnusson MK, Kraaij R, Leadley RM, De Ridder CM, van Weerden WM, et al. (2012) A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Hum Gene Ther 23: 70-82.
2. Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, et al. (2007) Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 14: 211-219.
3. Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, et al. (2009) Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther 20: 1214-1221.
4. Escutenaire S, Cerullo V, Diaconu I, Ahtiainen L, Hannuksela P, et al. (2011) In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments. Ann Med 43: 151-163.
5. de Vrij J, Uil TG, van den Hengel SK, Cramer SJ, Koppers-Lalic D, et al. (2008) Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX. Gene Ther 15: 978-989.
6. Mathis JM, Bhatia S, Khandelwal A, Kovesdi I, Lokitz SJ, et al. (2011) Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging. PLoS One 6: e16792.
7. Di B, Mao Q, Zhao J, Li X, Wang D, et al. (2012) A rapid generation of adenovirus vector with a genetic modification in hexon protein. J Biotechnol 157: 373-378.
8. Coughlan L, Bradshaw AC, Parker AL, Robinson H, White K,et al. (2012) Ad5:Ad48 Hexon Hypervariable Region Substitutions Lead to Toxicity and Increased Inflammatory Responses Following Intravenous Delivery. Mol Ther.
9. Yoshioka Y, Asavatanabodee R, Eto Y, Watanabe H, Morishige T, et al. (2008) Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sci 83: 747-755.
10. Yu D, Jin C, Leja J, Majdalani N, Nilsson B, et al. (2011) Adenovirus with hexon tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J Virol 85: 13114-13123.
11. Adams WC, Gujer C, McInerney G, Gall JG, Petrovas C, et al. (2011) Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation. Proc Natl Acad Sci U S A 108: 7499-7504.
12. Ni Choileain S, Astier AL, (2012) CD46 processing: A means of expression. Immunobiology 217: 169-175.
13. Tuve S, Wang H, Ware C, Liu Y, Gaggar A, et al. (2006) A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 80: 12109-12120.
14. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW (2008) Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 45: 659-662, 664-658.
15. Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M, et al. (2004) Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 6: 631-641.
16. Carlsson B, Cheng WS, Totterman TH, Essand M, (2003) Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol 121: 428-438.
17. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509-2514.
18. Danielsson A, Dzojic H, Nilsson B, Essand M, (2008) Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region. Cancer Gene Ther 15: 203-213.
19. Luo J, Deng ZL, Luo X, Tang N, Song WX, et al. (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247.
20. Leja J, Dzojic H, Gustafson E, Oberg K, Giandomenico V, et al. (2007) A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin Cancer Res 13: 2455-2462.
21. Maizel JV Jr, White DO, Scharff MD, (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36: 115-125.
22. Forsberg O, Carlsson B, Totterman TH, Essand M, (2008) Strategic use of an adenoviral vector for rapid and efficient ex vivo-generation of cytomegalovirus pp65-reactive cytolytic and helper T cells. Br J Haematol 141: 188-199.
23. Goto M, Eich TM, Felldin M, Foss A, Kallen R, et al. (2004) Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation 78: 1367-1375.
24. Friberg AS, Stahle M, Brandhorst H, Korsgren O, Brandhorst D, (2008) Human islet separation utilizing a closed automated purification system. Cell Transplant 17: 1305-1313.
25. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O, (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57: 11-20.
26. Adamson RE, Frazier AA, Evans H, Chambers KF, Schenk E, et al. (2012) In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus. Hum Gene Ther 23: 218-230.
27. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580.
28. Naldini L, (2011) Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12: 301-315.
29. Harlan DM, Kenyon NS, Korsgren O, Roep BO, (2009) Current advances and travails in islet transplantation. Diabetes 58: 2175-2184.
30. Flotte T, Agarwal A, Wang J, Song S, Fenjves ES, et al. (2001) Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. Diabetes 50: 515-520.
31. Bilbao G, Contreras JL, Dmitriev I, Smyth CA, Jenkins S, et al. (2002) Genetically modified adenovirus vector containing an RGD peptide in the HI loop of the fiber knob improves gene transfer to nonhuman primate isolated pancreatic islets. Am J Transplant 2: 237-243.
32. Molnar C, Essand M, Wennberg L, Berne C, Larsson E,et al. (2012) Islet Engraftment and Revascularization in Clinical and Experimental Transplantation. Cell Transplant.
33. Pietras A, (2011) Cancer stem cells in tumor heterogeneity. Adv Cancer Res 112: 255-281.
34. Maitland NJ, Collins AT, (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26: 2862-2870.
35. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, et al. (2003) Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 14: 777-787.
36. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, et al. (2006) Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 87: 2487-2495.
37. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A, (2005) Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79: 7478-7491.
38. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, et al. (2008) Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A 105: 5483-5488.
39. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
40. Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, et al. (2008) Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480.
41. Leissner P, Legrand V, Schlesinger Y, Hadji DA, van Raaij M, et al. (2001) Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther 8: 49-57.
42. Alemany R, Curiel DT, (2001) CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8: 1347-1353.
43. Mizuguchi H, Koizumi N, Hosono T, Ishii-Watabe A, Uchida E, et al. (2002) CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther 9: 769-776.
44. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, et al. (2001) Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 75: 11284-11291.
45. Yun CO, Yoon AR, Yoo JY, Kim H, Kim M, et al. (2005) Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity. Hum Gene Ther 16: 248-261.
46. Leja J, Nilsson B, Yu D, Gustafson E, Akerstrom G, et al. (2010) Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS One 5: e8916.
47. Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, et al. (2003) Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J Virol 77: 13062-13072.
48. Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T, (2003) Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 8: 813-821.
49. Mui TS, Kapp M, Einsele H, Grigoleit GU (2010) T-cell therapy for cytomegalovirus infection. Curr Opin Organ Transplant.